Dingchi Bio is committed to improving the quality of biological drugs with the world’s leading biopharmaceutical technology. At present, a complete new vaccine technology research platform, antibody drug research platform and pilot-scale expression platform have been established. With years of scientific research accumulation, we have developed fully suspended ST, PK-15, MDCK, Marc145, Vero and other cells, “true suspension” vaccine production technology, CHO cell antibody production technology, and 293 cell transient transfection technology. Recently, Dingchi Bio has completed hundreds of millions of B rounds of financing. This round of financing was jointly led by Materia Medica and Zhongken Fund; Yijing Capital, Liangshan Fund, Dongfang Fuhai, Zheke Investment, and Suxin Venture Capital also participated in the investment.
This article is reproduced from: https://www.itjuzi.com/investevent/13569026
This site is for inclusion only, and the copyright belongs to the original author.